Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 4/20 | 0.42 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.40 |
| ▸ | SLC26A4 | O43511 | 2/20 | 0.39 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.39 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.38 |
| ▸ | CFD | P00746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29623656 | 1.00 | PPARD (0.42) | PPARDPPARAPTGER4SLC26A4CYP26A1 | |
| Hydrochloric Acid SCHEMBL1224090 | 0.99 | PPARD (0.41) | PPARDPPARAPTGER4SLC26A4CYP26A1 | |
| SCHEMBL8310811 | 0.91 | PTGER4 (0.42) | PPARDPPARAPTGER4SLC26A4PPARG | |
| SCHEMBL8314225 | 0.89 | SLC26A4 (0.38) | PPARDPPARAPTGER4SLC26A4F2RL3 | |
| SCHEMBL8316517 | 0.89 | BCL2 (0.43) | PTGER4SLC26A4F2RL3KMT2AMEN1 | |
| SCHEMBL8314208 | 0.87 | F2RL3 (0.36) | PTGER4SLC26A4F2RL3KMT2AMEN1 | |
| SCHEMBL9061589 | 0.86 | F2RL3 (0.35) | PPARDPPARAPTGER4SLC26A4F2RL3 | |
| SCHEMBL8310775 | 0.86 | MAOB (0.42) | SLC26A4F2RL3KMT2AHDAC6 | |
| SCHEMBL8311549 | 0.85 | PTGER4 (0.40) | PPARDPPARAPTGER4SLC26A4 | |
| SCHEMBL8310234 | 0.85 | SLC26A4 (0.36) | PTGER4SLC26A4F2RL3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 784 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1898894-A1 | MRP IV INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2008-03-19 | — | — | EP | claimed |
| EP-1781298-A1 | PHARMACEUTICAL COMBINATIONS CONTAINING BENZOXAZINE FOR TREATING RESPIRATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-05-09 | — | — | EP | claimed |
| US-20070037781-A1 | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-15 | — | — | US | claimed |
| US-20060286041-A1 | MRP IV INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-21 | — | — | US | claimed |
| WO-2006134022-A1 | MRP IV INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-21 | — | — | WO | claimed |
| EP-1071463-B1 | METHODS AND COMPOSITIONS USING TERFENADINE METABOLITES IN COMBINATION WITH LEUKOTRIENE INHIBITORS | SEPRACOR INC (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005102349-A1 | PHARMACEUTICAL COMBINATIONS CONTAINING BENZOXAZINE FOR TREATING RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | claimed |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2005-10-27 | — | — | US | claimed |
| US-20050147564-A1 | A liquid, propellant-free mixtures for treating asthma or chronic obstructive pulmonary disease; tiotropium bromide | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-07-07 | — | — | US | claimed |
| US-6890517-B2 | Inhalable formulation of a solution containing a tiotropium salt | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-05-10 | — | — | US | claimed |
| US-20030181478-A1 | A liquid, propellant-free mixtures for treating asthma or chronic obstructive pulmonary disease; tiotropium bromide | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-25 | — | — | US | claimed |
| EP-1335729-A2 | INHALATIVE SOLUTION FORMULATION CONTAINING A TIOTROPIUM SALT | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-08-20 | — | — | EP | claimed |
| US-20020137764-A1 | .0005-5 wt% of a tiotropium salt, an antiallergic, antihistamine, steroid, or leukotriene antagonist, water or water/ethanol mixture and a preservative; antiasthmatics and chronic obstructive pulmonary disease treatment | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-09-26 | — | — | US | claimed |
| WO-2002036591-A2 | INHALATIVE SOLUTION FORMULATION CONTAINING A TIOTROPIUM SALT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-05-10 | — | — | WO | claimed |
| EP-0528337-B1 | New thiazolylbenzofuran derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1999-10-20 | — | — | EP | claimed |
| US-5296495-A | Antiallergens, antiinflammatory | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-03-22 | — | — | US | claimed |
| JP-10316678-A | — | — | None | — | — | JP | disclosed |
| EP-3643309-B1 | NINTEDANIB FOR USE IN THE TREATMENT OF SYSTEMIC SCLERODERMA | BOEHRINGER INGELHEIM INT (DE) | 2025-12-03 | — | — | EP | disclosed |
| US-5296495-A | Antiallergens, antiinflammatory | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-03-22 | — | — | US | disclosed |
| EP-0528337-A1 | New thiazolylbenzofuran derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050147564-A1 | A liquid, propellant-free mixtures for treating asthma or chronic obstructive pulmonary disease; tiotropium bromide | LTA4H, LTB4R, LTB4R2 | PPARD 246/4885PPARA 176/4885PTGER4 19/4885 |
| US-20070037781-A1 | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | ADRB2, ADRA2A, ADRB1 | PPARD 514/4885PPARA 478/4885PTGER4 84/4885 |
| US-20020137764-A1 | .0005-5 wt% of a tiotropium salt, an antiallergic, antihistamine, steroid, or leukotriene antagonist, water or water/ethanol mixture and a preservative; antiasthmatics and chronic obstructive pulmonary disease treatment | LTA4H, IL5, LTB4R | PPARD 281/4885PPARA 227/4885PTGER4 18/4885 |
| US-20060286041-A1 | MRP IV INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | ABCB1, ABCC4, ABCC1 | PPARD 1082/4885PPARA 1764/4885PTGER4 321/4885 |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | MRGPRX2, MRGPRX1, MTNR1B | PPARD 1249/4885PPARA 1294/4885PTGER4 127/4885 |
| US-20030181478-A1 | A liquid, propellant-free mixtures for treating asthma or chronic obstructive pulmonary disease; tiotropium bromide | LTA4H, LTB4R, LTB4R2 | PPARD 246/4885PPARA 176/4885PTGER4 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.